Showing 2531-2540 of 5909 results for "".
- Regenxbio Presents Positive Interim Data From Phase 2 ALTITUDE Trial of RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-presents-positive-interim-data-from-phase-3-altitude-trial-of-rgx-314-for-treatment-of-diabetic-retinopathy-using-suprachoroidal-delivery/2480639/Regenxbio announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogene
- Glaukos Announces Executive Leadership Changeshttps://modernod.com/news/glaukos-announces-executive-leadership-changes/2480628/Glaukos announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer.
- Hubble Lenses Fined Millions After Settling Charges it Violated the Contact Lens Rule and FTC Act to Boost Saleshttps://modernod.com/news/hubble-lenses-fined-millions-after-settling-charges-it-violated-the-contact-lens-rule-and-ftc-act-to-boost-sales/2480604/New York City-based Vision Path, the online seller of direct-to-consumer Hubble lenses, will pay penalties and redress totaling $3.5 million to settle Federal Trade Commission (FTC) charges that it violated the Contact Lens Rule in several ways, including by failing to obtain prescriptions and to
- New Paper Examines Top 10 Myths About Fitting Soft Contact Lenseshttps://modernod.com/news/new-paper-examines-top-10-myths-about-fitting-soft-contact-lenses/2480598/A new peer-review paper from the Centre for Ocular Research & Education (CORE) seeks to shift persistent views about contact lenses that are no longer accurate based on current evidence. Addressing common myths and mis
- Mitotech to Host Key Opinion Leader Webinar on Visomitin: A Potential Treatment for Dry Eye Diseasehttps://modernod.com/news/mitotech-to-host-key-opinion-leader-webinar-on-visomitin-a-potential-treatment-for-dry-eye-disease/2480596/Mitotech announced that it will host a key opinion leader (KOL) webinar on Visomitin and its potential for the treatment of dry eye disease, on Friday, February 4, 2022 at 8 am EST (14.00 CET). The event will feature presentations from John D. Sheppard, MD, MMSc (Virginia Eye Consu
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- Johns Hopkins: Study Finds Up to 30% of Patients with Wet Macular Degeneration May Safely Stop Eye Injectionshttps://modernod.com/news/johns-hopkins-study-finds-up-to-30-of-patients-with-wet-macular-degeneration-may-safely-stop-eye-injections/2480583/In a preliminary study of 106 people with wet age-related macular degeneration (AMD), Johns Hopkins Medicine researchers report that as many as a third of those with the blinding retinal disease may someday be able to safely stop eye injection therapy without further vision loss. The fi
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- AffaMed Therapeutics, licensee of Dextenza in Certain Asian Markets, Doses Their First Patient in Clinical Trial in Cataract Surgery Patientshttps://modernod.com/news/affamed-therapeutics-licensee-of-dextenza-in-certain-asian-markets-doses-their-first-patient-in-clinical-trial-in-cataract-surgery-patients/2480574/Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain post-cataract surger
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell